express scripts glp 1 coverage does cover GLP-1 drug use driving up health care costs 2026 with Express Scripts – Understanding GLP-1s | Express Scripts®

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators

Preserving muscle matters

For researchers considering a taper schedule, the dosage calculator can help plan the exact reconstitution volumes needed at each reduced dose tier

The proposed mechanism suggests that caffeine and other coffee compounds absorbed through the colonic mucosa might stimulate the liver's production of glutathione S-transferase, an enzyme involved in detoxification pathways

Why this matters: injectable GLP-1s like semaglutide and tirzepatide achieve 15 to 20% weight reductions, but injections, cost, and adherence limit real-world use (Santulli review, Journal of Diabetes & Metabolic Disorders, 2025)

People with middle- and late-stage dementia can't usually drive, cook, or live alone